Compound Radar

Nuvation Bio Inc. (NUVB) Stock Analysis

United States · Healthcare / Biotechnology

Price $6.61
Market cap $2.32B
Next earnings Nov 2, 2026
Entry status Wait

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

45
45/100 Speculative
  • Financial Health 40
  • Profitability 25
  • Business Quality 65
  • Balance Sheet 45
  • Cash Flow 60

Why this rating?

Health 45/100 — Speculative

Strongest Business Quality 65/100
Softest Profitability 25/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

Nuvation Bio Inc. (NUVB) is a Biotechnology company in the Healthcare sector. Compound Radar rates Nuvation Bio Inc. 45/100 (Speculative) due to solid business quality, strong revenue growth, and elevated leverage.

Investment profile

  • Quality Moderate
  • Growth Strong
  • Balance Sheet Stretched

Financial highlights

Valuation

  • Forward P/E -440.67
  • EV/Revenue 12.63

Profitability

  • Revenue Growth 555.6%
  • Gross Margin 88.2%
  • Operating Margin -161.1%
  • Net Margin -88.2%
  • ROE -47.8%

Financial strength

  • Cash $660.96M
  • Debt $416.26M
  • Net Cash $244.69M
  • Free Cash Flow $-181.78M
  • Current Ratio 8.37

Similar companies

Peers in Biotechnology, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Biotechnology →

FAQ

How Compound Radar scores and tracks Nuvation Bio Inc. (NUVB).

View Methodology & FAQ →